Feasibility of Semaglutide in Advanced Lung Disease

• Status: Not yet recruiting
• Trial end date: 2024-02-28
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.

The main question[s] it aims to answer are:

1. Are patients with advanced lung disease able to tolerate semaglutide therapy?

2. Are we able to titrate semaglutide therapy to a target weight?

Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania

Criteria

Inclusion Criteria:

• Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension

• Age > 18

• BMI > 30 kg/m2

• Requires supplemental oxygen on exertion

• Stable treatment regimen X 90 days

• Use of disease-modifying therapy

Exclusion Criteria:

• Diabetes

• Pregnant or Breastfeeding

• Recent weight loss

• Recent or chronic GI complaints

• History of gastroparesis

• History of scleroderma

• Hospitalized at time of evaluation

• Use of weight loss medication in last 90 days

• Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)

• Uncontrolled thyroid disease

• History of acute/chronic pancreatitis

• Prior suicide attempt

• Suicidal ideation in last 90 days

• Presence of a pacemaker or defibrillator